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An important study by Petros Skapinakis and colleagues1 
in The Lancet Psychiatry compares the eﬃ  cacy of 
pharmacological and psychotherapeutic treatment 
strategies for adults with obsessive-compulsive dis-
order. The authors should be commended for having 
systematically reviewed just over 36 years of literature 
(1980–2016) and for using a new analytical approach—
network meta-analysis—which allows for simultaneous 
comparison of several treatments in a single model and 
has been previously applied to other mental disorders.2 
The network meta-analysis1 included 54 randomised 
controlled trials (RCTs) and 6652 participants. 
This comprehensive, carefully done study1 is 
an example of how obtaining of evidence-based 
information to guide clinical practice is challenging, 
even in a well explored research area. Despite the large 
number of published RCTs, important clinical questions 
remain unanswered concerning obssessive-compulsive 
disorder treatment. As properly acknowledged by 
the authors, several gaps in knowledge remain to be 
addressed in future research. One of these gaps is that 
no potential diﬀ erences in the eﬃ  cacies of individual 
SSRIs or between SSRIs as a group and clomipramine 
could be shown; they seemed to be equally eﬀ ective. 
The mean Yale-Brown Obsessive Compulsive Scale 
diﬀ erence was –3·49 (95% credible interval –5·12 
to –1·81) for SSRIs and –4·72 (–6·85 to –2·60) for 
clomipramine. The authors could not examine whether 
higher doses of the same drug are associated with 
greater treatment responses. Likewise, when studies 
that used waiting list control groups were excluded, 
the eﬀ ects of recommended psychotherapies were 
similar in magnitude. The mean Yale-Brown Obsessive 
Compulsive Scale diﬀ erence was –10·41 (95% credible 
interval –14·04 to –6·77) for behavioural therapy, 
–9·45 (–13·76 to –5·19) for cognitive therapy, and 
was patient rated (rather than clinician rated) is even 
more worthwhile to highlight. The patient’s point of 
view is increasingly sought because, in the end, it is the 
patient not the doctor who must take the medication. 
Diﬀ erences between the full versus the per-protocol 
sample are common because clinically important events, 
such as poor eﬃ  cacy or unpleasant side eﬀ ects, can 
cause patients to withdraw from a study prematurely, 
such that the ﬁ nal per-protocol results do not reﬂ ect 
the important diﬀ erences between the interventions. 
However, the diﬀ erence in CGI eﬃ  cacy index (CGI minus 
side eﬀ ects at 6 weeks) was signiﬁ cant, suggesting that 
the index is driven by a side-eﬀ ect diﬀ erence. 
Further analyses could explore whether the quality-
of-life diﬀ erences were mediated by changes in 
extrapyramidal symptoms. Unfortunately, the subjective 
well being under neuroleptic treatment (SWN-K) scale 
(high with FGAs) was not given at each visit, which 
might have shed light on the mechanisms. 
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–7·98 (–11·02 to –4·93) for cognitive behavioural 
therapy. Therefore, the speciﬁ c aspects of these 
approaches that are most eﬀ ective are unclear. 
Another point is that although the eﬀ ect of 
psycho therapeutic interventions was greater 
than that of medications, pure psychotherapeutic 
and pharmacological treatments could not 
be compared directly because most studies of 
psychotherapy included patients taking stable doses 
of antidepressants. Considering the short median 
duration of the RCTs included in the analysis (12 weeks 
[IQR 10–12]), medium-term and long-term responses 
to treatment are important aspects warranting 
further study. Obsessive-compulsive disorder is usually 
a long-lasting condition, and consistent clinical 
improvement might take much longer than 3 months 
to achieve. Almost all of the RCTs included in the 
analysis involved interventions recommended for 
obsessive-compulsive disorder in current guidelines 
(SSRIs, clomipramine, and behavioural and cognitive 
therapies). The eﬀ ectiveness of other medications and 
forms of psychotherapy (eg, psychodynamic therapies) 
therefore remains largely unknown. 
Individual and group formats of behavioural or 
cognitive interventions were not compared. In trials 
that used both formats, data were extracted only 
for groups with the individual format. Nevertheless, 
some characteristics and therapeutic factors of group 
psychotherapy (eg, universality, instillation of hope, 
altruism, socialising, and interpersonal learning)3 
might be particularly important for patients with 
obsessive-compulsive disorder who are usually 
ashamed of their symptoms and feel hopeless and 
socially isolated.4 Obsessive-compulsive disorder is a 
mosaic of diverse phenomenological manifestations, 
and some symptom dimensions (eg, hoarding 
symptoms) seem to have a worse response to 
treatment than do other symptoms.5 Thus, possible 
phenotypic diﬀ erences in treatment response are 
a relevant yet underexplored clinical aspect. Even 
though comorbidities (except for schizophrenia and 
bipolar disorder) were allowed in most RCTs included 
in the analysis, the authors could assess only the 
eﬀ ect of depression—the most common comorbidity 
in obsessive-compulsive disorder—because of an 
absence of information. Other disorders (including 
anxiety, somatoform, impulse control, trauma-related, 
substance use, and personality disorders) are very 
common among patients with obsessive-compulsive 
disorder and can aﬀ ect adherence and response to 
treatment.6 
Several other factors that can inﬂ uence treatment 
response should be explored in future research, 
including the quality of the professional-patient 
therapeutic alliance;7 level of insight,8,9 which varies 
considerably between patients and within the same 
patient over time or according to symptom dimensions; 
and family accommodation to the symptoms.9,10 Family 
accommodation is a very common phenomenon 
in obsessive-compulsive disorder and has been 
associated with treatment refractoriness.9,10 Skapinakis 
and colleagues’ network meta-analysis focused on 
adults with non-refractory obsessive-compulsive 
disorder; future studies are warranted for children and 
adolescents. For refractory patients, several altern-
ative interventions have been investigated, mostly 
in the last decade, including pharmacological (eg, 
adjunctive antipsychotics, memantine, riluzole, ket-
amine, ondansetron, lamotrigine, topiramate, 
pregabalin, and gabapentin),9,11 somatic (eg, deep-brain 
stimulation, transcranial magnetic stimulation, and 
limbic surgery),9,11 psychological (eg, psychoeducation, 
family and motivational interventions, and intensive 
residential psychotherapy),9 and mixed approaches 
(eg, d-cycloserine as an augmentation strategy of 
behavioural therapy).9 Beyond symptom reduction, 
improvement in quality of life is a crucial treatment 
goal to be monitored, as well as factors associated with 
relapse after successful treatment. This secret, complex, 
chronic, and debilitating disorder requires increased 
identiﬁ cation and improved access to evidence-based 
treatments in the ﬁ rst place.12 Delayed help seeking4 
and an inadequate number of well trained health 
professionals are important problems to be addressed. 
For all of these reasons, “a long and winding road” 
still lies ahead before the distress of patients with 
obsessive-compulsive disorder and their families is 
really alleviated.
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More than 800 000 people die by suicide every year, 
and for each suicide there are at least 20 others 
attempting suicide. Intentional self-harm is often 
repeated and associated with risks for future suicide. 
According to WHO,1 prevention of suicide is a global 
imperative, as suicide and suicidal behaviours 
constitute a growing problem in most countries 
and health-care systems require large amounts of 
resources to address them.
Hawton and colleagues’ systematic review and 
meta-analysis in The Lancet Psychiatry on the eﬃ  cacy 
of psychosocial interventions after self-harm in adults 
is both meticulous and a necessary update of an earlier 
review of psychosocial and pharmacological treatments 
in the prevention of repetition of deliberate self-harm.2,3 
The present publication points to the eﬀ ectiveness 
of both cognitive behavioural therapy and dialectical 
behaviour therapy in the prevention of repetition of 
self-harm. These results will hopefully assist policy 
makers and clinical practitioners to choose evidence-
based options for treatment. 
Cognitive behavioural therapy recognises the 
central role of cognitive factors in the development 
and maintenance of suicidal behaviour, whereas 
dialectical behaviour therapy emphasises emotion 
dysregulation and interpersonal dysfunction. In the 
prevention of suicide, such therapies focus on training 
of problem-solving skills, alongside the improvement 
of social capacity by monitoring situations that 
provoke anxiety, depressive feelings, and destructive 
thoughts and behaviours. Moreover, they provide help 
with cognitive restructuring, improve interpersonal 
relationships, reinforce adaptive behaviours, and 
emphasise commitment to change the destructive 
behaviour. Hopelessness is reduced when a suicidal 
individual perceives increased self-eﬃ  cacy in solving 
problems. A sense of hope is conveyed through psycho-
education and increased knowledge about how to 
diminish distress, while increasing assertiveness, 
emotional regulation, and motivation through 
discussion of reasons for living. 
Psychosocial therapies are contact oriented. The 
opportunity to discuss existential problems in a 
safe environment with a professional who pays 
attention is probably one of the key components of 
therapeutic success.4 The fact that this therapy includes 
encouragement by a therapist who actively responds 
to diﬃ  culties matters, because suicidal people often 
do not have attention and encouragement in their 
lives; many are tormented by traumatic childhood 
experiences and an absence of positive role models.3 
Suicidal behaviour is triggered by the interplay of social, 
cultural, psychological, economical, biological, societal 
(environmental), and existential factors. With this in 
mind, the need for meaningful human interactions 
cannot be underestimated.5 
Interestingly, Hawton and colleagues show that there 
are other promising psychosocial interventions or 
Psychosocial interventions to prevent repeated self-harm
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